Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.
作者信息
Rau R
机构信息
Department of Rheumatology, Evangelisches Fachkrankenhaus Ratingen, Ratingen, Germany.
出版信息
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii70-3. doi: 10.1136/ard.61.suppl_2.ii70.
Abstract
摘要
相似文献
1
Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.阿达木单抗（一种全人源抗肿瘤坏死因子α单克隆抗体）治疗活动性类风湿关节炎：五项试验的初步结果。
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii70-3. doi: 10.1136/ard.61.suppl_2.ii70.
2
Adalimumab for rheumatoid arthritis.阿达木单抗用于治疗类风湿性关节炎。
Expert Opin Biol Ther. 2006 Dec;6(12):1349-60. doi: 10.1517/14712598.6.12.1349.
3
[Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].[全人源抗TNF-α单克隆抗体（阿达木单抗、戈利木单抗）]
Nihon Rinsho. 2007 Jul;65(7):1202-8.
4
Adalimumab therapy in rheumatoid arthritis.阿达木单抗治疗类风湿关节炎。
Rheum Dis Clin North Am. 2004 May;30(2):349-64, vii. doi: 10.1016/j.rdc.2004.02.004.
5
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).阿达木单抗，一种全人源抗肿瘤坏死因子-α单克隆抗体，联合标准抗风湿疗法治疗类风湿关节炎：STAR（阿达木单抗治疗类风湿关节炎安全性试验）结果
J Rheumatol. 2003 Dec;30(12):2563-71.
6
Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.阿达木单抗：一种用于治疗银屑病关节炎的抗TNF药物。
Expert Opin Biol Ther. 2005 Nov;5(11):1491-504. doi: 10.1517/14712598.5.11.1491.
7
Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.类风湿关节炎中对抗肿瘤坏死因子药物的差异耐药性
Ann Rheum Dis. 2006 Jun;65(6):701-3. doi: 10.1136/ard.2005.049890.
8
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.类风湿关节炎中抗 TNF 抗体治疗与严重感染及恶性肿瘤风险：随机对照试验中罕见有害效应的系统评价和荟萃分析
JAMA. 2006 May 17;295(19):2275-85. doi: 10.1001/jama.295.19.2275.
9
Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.D2E7最新进展：一种完全人源化的抗肿瘤坏死因子α单克隆抗体。
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i44-5. doi: 10.1136/ard.59.suppl_1.i44.
10
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.全人源抗肿瘤坏死因子α单克隆抗体阿达木单抗（D2E7）在对改善病情抗风湿药（DMARD）治疗无效的类风湿关节炎患者中的疗效和安全性：一项为期12周的II期研究。
Ann Rheum Dis. 2003 Dec;62(12):1168-77. doi: 10.1136/ard.2003.009563.
引用本文的文献
1
Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms-a comprehensive review.心血管-肾脏-代谢综合征中的炎症：关键作用及潜在机制——综述
Mol Cell Biochem. 2025 Sep 10. doi: 10.1007/s11010-025-05379-9.
2
Rheumatoid arthritis severity is mediated by crosstalk between synoviocytes and mature osteoclasts through a calcium and cytokine feedback loop.类风湿性关节炎的严重程度是由滑膜细胞和成熟破骨细胞之间通过钙和细胞因子反馈回路的相互作用介导的。
Exp Mol Med. 2025 Feb;57(2):402-419. doi: 10.1038/s12276-025-01401-8. Epub 2025 Feb 3.
3
What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022.在优化阿达木单抗治疗中，治疗药物监测的益处有哪些？截至2022年的系统评价和荟萃分析
Front Pharmacol. 2024 Jul 8;15:1376708. doi: 10.3389/fphar.2024.1376708. eCollection 2024.
4
Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases.噬菌体展示技术在生物标志物鉴定中的应用，重点是非癌症疾病。
Molecules. 2024 Jun 25;29(13):3002. doi: 10.3390/molecules29133002.
5
A Novel 3D-Printed and Miniaturized Periodic Counter Current Chromatography System for Continuous Purification of Monoclonal Antibodies.一种用于连续纯化单克隆抗体的新型3D打印小型化周期逆流色谱系统。
Micromachines (Basel). 2024 Mar 13;15(3):382. doi: 10.3390/mi15030382.
6
A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.对美国食品药品监督管理局基于组学的药效学生物标志物以确立生物相似性的批判性分析。
Pharmaceuticals (Basel). 2023 Nov 2;16(11):1556. doi: 10.3390/ph16111556.
7
Tumor Necrosis Factor: What Is in a Name?肿瘤坏死因子：名称中有何含义？
Cancers (Basel). 2022 Oct 27;14(21):5270. doi: 10.3390/cancers14215270.
8
A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis.一种新型抗 TNF-α 药物奥扎鲁单抗在胶原诱导性关节炎的小鼠模型中迅速分布到炎症关节组织中。
Sci Rep. 2022 Oct 27;12(1):18102. doi: 10.1038/s41598-022-23152-6.
9
Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.基因本体分析突显影响类风湿关节炎抗TNF治疗无反应的生物学过程。
Biomedicines. 2022 Jul 27;10(8):1808. doi: 10.3390/biomedicines10081808.
10
Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models.恢复促炎细胞因子与抗炎细胞因子之间的平衡在类风湿关节炎治疗中的作用：来自动物模型的新见解
Biomedicines. 2021 Dec 26;10(1):44. doi: 10.3390/biomedicines10010044.
本文引用的文献
1
Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.与甲氨蝶呤相比，全人源抗肿瘤坏死因子-α抗体单药治疗长期类风湿关节炎的药物生存期、疗效及毒性
Rheumatology (Oxford). 2002 Apr;41(4):430-9. doi: 10.1093/rheumatology/41.4.430.
2
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.类风湿关节炎的长期抗肿瘤坏死因子α单药治疗：对放射学病程的影响以及软骨更新和内皮激活标志物的预后价值
Ann Rheum Dis. 2002 Apr;61(4):311-8. doi: 10.1136/ard.61.4.311.
3
Rheumatoid arthritis.类风湿关节炎
Lancet. 2001 Sep 15;358(9285):903-11. doi: 10.1016/S0140-6736(01)06075-5.
4
Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.全人源抗肿瘤坏死因子α单克隆抗体治疗对类风湿关节炎患者白细胞介素1和肿瘤坏死因子α局部及全身稳态的影响
Ann Rheum Dis. 2001 Jul;60(7):660-9. doi: 10.1136/ard.60.7.660.
5
Cytokine pathways and joint inflammation in rheumatoid arthritis.类风湿关节炎中的细胞因子通路与关节炎症
N Engl J Med. 2001 Mar 22;344(12):907-16. doi: 10.1056/NEJM200103223441207.
6
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.用重组人肿瘤坏死因子受体（p75）-Fc融合蛋白治疗类风湿性关节炎。
N Engl J Med. 1997 Jul 17;337(3):141-7. doi: 10.1056/NEJM199707173370301.
7
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.欧洲抗风湿病联盟类风湿关节炎反应标准的制定与验证。与美国风湿病学会初步标准及世界卫生组织/国际抗风湿病联盟标准的比较。
Arthritis Rheum. 1996 Jan;39(1):34-40. doi: 10.1002/art.1780390105.
8
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.美国风湿病学会类风湿关节炎临床试验疾病活动度测量初步核心指标集。类风湿关节炎临床试验结果测量委员会。
Arthritis Rheum. 1993 Jun;36(6):729-40. doi: 10.1002/art.1780360601.
9
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.嵌合型肿瘤坏死因子α单克隆抗体（cA2）与安慰剂治疗类风湿关节炎的随机双盲对照研究
Lancet. 1994 Oct 22;344(8930):1105-10. doi: 10.1016/s0140-6736(94)90628-9.
10
Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.肿瘤坏死因子α刺激软骨中蛋白聚糖的吸收并抑制其合成。
Nature. 1986;322(6079):547-9. doi: 10.1038/322547a0.
Zotero 插件